Trial Profile
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation
- Focus Adverse reactions
- Acronyms RASMET
- Sponsors Enterin
- 27 Aug 2019 According to an Enterin Media Release, the results of this study were published in the Clinical Parkinsonism and Related Disorders.
- 27 Aug 2019 Results published in the Enterin Media Release
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.